Clinical trial

Intranasal Ketamine in Treatment-Resistant Depression

James MurroughCompletedStarted Oct 1, 201120 enrolledUnited StatesNCT01304147

Abstract

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

treatment resistanceintranasal, antidepressantglutamateNMDA receptorMajor Depressive Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025